Eisai R&d Management Co., Ltd.

Xiang Liu

Sudeep Prajapati

Dominic J Reynolds

Andrew Cook

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

James Palacino

Shelby Ellery

Thiwanka Samarakoon

Megan Sheehan

John JianShi Wang

Guo Zhu Zheng

Nathan Elliott Fishkin

Yoshihiko Kotake

Gregg F Keaney

Ping Zhu

Kazunobu Kira

Parcharee Tivitmahaisoon

Norio Murai

Baudouin Gerard

Michael W Seiler

Satoshi Nagao

Masayuki Miyano

Kenzo Arai

Regina Mikie Kanada Sonobe

Nicholas C Gearhart

Yonghong Xiao

Nicholas Calandra

Zhenhua Wu

Atsushi Endo

Jason T Lowe

Eunice Sun Park

Kian Huat Lim

Michael P Thomas

Betty Chan

Shouyong Peng

Ming-Hong Hao

Cheng Zhong

Arani Chanda

Lei Zhou

Lisa A Marcaurelle

Tuoping Luo

Morgan Welzel O'shea

Ryan Brawn

Regina Mikie Kanada Sonabe

Huafeng Lin

Frank Effenberger

Huaiyu Zeng

Regina Kanada Sonobe

Sundeep Prajapati

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Growing community of inventors

Winchester, MA, United States of America

Xiang Liu